What did SOPHiA GENETICS (SOPH) Chief Medical Officer Philippe Menu report in this Form 4?

Philippe Menu reported selling 5,000 SOPHiA GENETICS Ordinary Shares in an open-market transaction. The sale used a weighted average price of $4.6689 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan.

How many SOPHiA GENETICS (SOPH) shares does Philippe Menu hold after this sale?

After selling 5,000 Ordinary Shares, Philippe Menu directly holds 256,388 SOPHiA GENETICS shares. This post-transaction balance reflects his remaining direct ownership position following the reported open-market sale on May 12, 2026.

How many shares in total did Philippe Menu sell of SOPHiA GENETICS (SOPH) in this transaction?

The Form 4 shows that Philippe Menu sold 5,000 SOPHiA GENETICS Ordinary Shares. This represents the total number of shares involved in the reported open-market sale executed on May 12, 2026 under his 10b5-1 trading plan.

SOPHiA GENETICS (SOPH) CMO pre-planned sale of 5,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($23,345)

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,000	$4.6689	$23K

Holdings After Transaction: Ordinary Shares — 256,388 shares (Direct, null)

Footnotes (1)

Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.56 to $4.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $4.6689 per share Sale price range: $4.56 to $4.85 per share +2 more

5 metrics

Shares sold 5,000 shares Open-market sale on May 12, 2026

Weighted average sale price $4.6689 per share Ordinary Shares sold in multiple transactions

Sale price range $4.56 to $4.85 per share Range for multiple sale transactions

Shares held after transaction 256,388 shares Direct ownership after May 12, 2026 sale

Net shares sold 5,000 shares Net-sell direction in this Form 4

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE

1180

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	05/12/2026		S		5,000⁽¹⁾	D	$4.6689⁽²⁾	256,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.56 to $4.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

At what prices were the SOPHiA GENETICS (SOPH) shares sold in this insider transaction?

The reported weighted average sale price was $4.6689 per share. Shares were sold in multiple trades at prices ranging from $4.56 to $4.85, and detailed price breakdowns are available on request from the issuer or the SEC staff.

Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing notes that the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans pre-schedule trades, reducing the significance of trade timing as a signal of the insider’s short-term views.

Who is the insider involved in this SOPHiA GENETICS (SOPH) Form 4 filing and what is their role?

The insider is Philippe Menu, who serves as Chief Medical Officer of SOPHiA GENETICS SA. His role is as a company officer, and this Form 4 reports his personal open-market sale of 5,000 Ordinary Shares held directly.